Insulin content of isolated pancreas and islet morphology.

Slides:

Advertisements

Similar presentations

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Advertisements

INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice. INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice.

Percentages of children with autoimmune type 1 diabetes who carried the TCF7L2 rs TT genotype, expressed ICA512/IA2 or ZnT8 autoantibodies, presented.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Immunohistochemical analysis.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

The adipose tissue of BALB/c scid mice is quantitatively, but not qualitatively, different than that of BALB/c control mice. The adipose tissue of BALB/c.

Changes in BG levels from 60 min (immediately before the first stair climbing–descending exercise (ST-EX)) to 180 min postmeal. Changes in BG levels from.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

MRNA expression levels of the gene encoding CAR in explanted human islets from control donors, cultured in UV-treated culture medium derived from CBV-infected.

Viability and function of mouse pancreatic cell line.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Glucose-stimulated insulin secretion in virus-infected human islets.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Plasma adiponectin levels by race/ethnicity (1A) and gender (1B) among study participants who developed prediabetes/diabetes (Progressors, P) compared.

Metabolic syndrome—participants with four and five components—expected and observed frequencies by age. Metabolic syndrome—participants with four and five.

Metabolic syndrome—participants with only three components—expected and observed frequencies by age. Metabolic syndrome—participants with only three components—expected.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Morphology of cells used throughout the experiments.

mpJX-594 effects on tumor burden and leukocyte influx.

(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Obese gestational diabetes mellitus (GDM) women demonstrate significant dyslipidemia at 26 weeks of gestation compared to obese women without diabetes.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

MRNA expression levels of the gene encoding CAR in isolated human islets from control donors, cultured for prolonged time (n=2). mRNA expression levels.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Representative images of human islets infected with strains of CVB

(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Homeostasis model assessment of insulin resistance (HOMA-IR) scores in obese women and obese women with gestational diabetes mellitus (GDM) at approximately.

WASH cKO mice display a normal pancreatic development.

Pancreatic β-cell proliferation.

Serum adiponectin is significantly lower in obese gestational diabetes mellitus (GDM) women compared with obese women at 26 weeks of gestation. Serum adiponectin.

Fragment N expression does not affect islet morphology and cellularity

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Immunoblotting samples (A and F) and densitometric analysis of ASC1 (B and G), NLRP3 (C and H), TNFα (D and I) and Caspase-1 (E and J) expression in the.

T1D is reduced in CT-treated NOD mice.

Insulitis is reduced in CT-treated RIP-LCMV-GP mice.

(A) Hemoglobin A1c (HbA1c) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (B) Urinary albumin to creatinine.

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

Chop deletion preserves β-cell function in P58IPK−/− mice.

Lung-derived mesenchymal stem cells (MSC) display impaired bone formation capacity in vivo. Lung-derived mesenchymal stem cells (MSC) display impaired.

Reversal of diabetes-induced depletion of bone marrow (BM)–resident LSK cells and impairment of proliferation by ANG-(1-7) treatment. Reversal of diabetes-induced.

Urinary albumin excretion and histology of glomeruli.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Increased pancreatic insulin content and islet size and protection against HFD- and palmitate-induced cell death in PKCδKN-overexpressing mice. Increased.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

Western blot analysis of explanted human islets from control donors infected in vitro with CBV-1-11 revealed decreased expression of the CAR protein compared.

Presentation transcript:

Insulin content of isolated pancreas and islet morphology. Insulin content of isolated pancreas and islet morphology. The insulin content of isolated pancreas was measured 3 weeks after the end of treatment (day 37) in multiple low-dose streptozotocin-induced diabetic mice (MLDS mice) (A). Pancreatic islets of the isolated pancreases were stained with H&E on day 37 in MLDS mice (B). (a) Control (Dulbecco's modified Eagle's medium, DMEM); (b) conditioned medium from human exfoliated deciduous teeth (SHED-CM); (c) exendin-4 (Ex-4); and (d) bone marrow-derived mesenchymal stem cells (BM-CM). The data are presented as a mean±SEM value. Scale bars, 100 μm.*p<0.05 versus control; †p<0.05 versus Ex-4; §p<0.05 versus BM-CM. Takako Izumoto-Akita et al. BMJ Open Diab Res Care 2015;3:e000128 ©2015 by American Diabetes Association